Early detection and timely treatment hold the key to cure retinopathy of prematurity (ROP). ROP screening is carried out unevenly in China. Examination equipments and personnel experiences are the major factors to constraint ROP screening. In addition to strengthening personnel training, it is necessary to establish a standard guideline and pipeline for ROP consultation and referral. Laser photocoagulation and cryotherapy are the first options for the threshold ROP and Type 1 prethreshold ROP. Scleral buckling or vitrectomy is needed for advanced ROP when retinal detachment occurs. The clinical efficacy of intravitreal injection of bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody) for severe ROP is encouraging, but needs further verification. Genetic interference and stem cell therapy will be the prosperous futures in the treatment of ROP. The screening and treatment of ROP in China is becoming more common and improved, but it is still a long way to go considering the huge population of China.
Objectives To observe the characteristics of occurrence a nd progres s of retinopathy of prematurity (ROP) in premature infants and search the reason able ROP screening time and therapeutic methods.〓〖WTHZ〗Methods〓〖WTBZ〗ROP s creening was perf ormed on 829 infants, with the gestational agele;35 weeks and the birth weightle; 2000 g, by indirect ophthalmoscopy combined with scleral pressurizing implement. Thirtytwo infants with prethreshold type I and threshold ROP underwent cryot he rapy. The followup duration after the operation was 316 months, and the crit er ia of the control of the diseases included: alleviation of the plus disease, all eviation of the vascular ridge, formation of the cryospots, absorption of vitr e oretinal hemorrhage, and non bad retinal structure. If the disease was not contr olled, recryotherapy or vitrectomy would be carried out.〓〖WTHZ〗Results〓〖W TBZ〗ROP was fou nd in 86 infants (172 eyes). The difference of oxygen duration time among ROP g roups and nonROP group was significant; the occurrence rate of ROP in the infa n ts with the birth weightle;1000 g, 10011500 g and 15012000 g was 6956%, 16 38% , and 414%, respectively; the occurrence rate of ROP in the infants with the g estat ional agele;30 weeks, 3132 weeks, and 3335 weeks was 37.14%, 10.43%, and 2.91 %, respectively; the occurrence rate of ROP in singleembryo infants group and mul t iple embryo infants group was 7.52% and 20.22%, respectively. Favorable outcom e was observed in 30 out of 32 infants who had undergone cryotherapy; 2 infants d eveloped retinal detachment with plus disease and peripheral retinal hemorrhage. The sccess rate of cryotherapy is high in the infants with the gestational age lt;32 weeks.〓〖WTHZ〗Conclusions〓〖WTBZ〗The ROP incidence rate is higher in the infants with lo ng oxygenbreathing duration, birth weighle;1000 g, and gestational age le; 32 we ek infants, which should be screened carefully. The infants having ROP onset within 32 weeks, with plus disease, and peripheral retinal hemorrhage should be follow ed up closely. The prognosis of cryotherapy for type I prethreshold and thresh old ROP is good and the operation is safe.
Objective：To observe the therapeutic ef fect of chemoreduction treatm ent combined with local focal therapy for advanced intraocular retinoblastoma (R B). Methods：Thirteen eyes of nine patients with RB underwent c hemoreduction tr eatment combined with local cryotherapy and (or) transpupillary thermotherapy (TTT), and the clinical data of the patients were retrospectively analyzed. The vi ncristine, etoposide, and carboplatin (VEC) were used in the chemoreduction trea tment. The average followup duration was 15.3 months. Results：All of the 13 e yes with RB had favorable initial reaction in the treatment of chemoreduction. A fter the first period of chemotherapy, the largest diameter of the tumor fundus decreased 37.2%, and the tumor thickness averagely reduced 46.7%. The subretinal fluid was absorbed completely or partially in 6 eyes (6/8); vitreous and subret inal seeds reduced, disappeared or calcified in 10 (10/11) and 11 eyes (11/11), respectively. During the treatment and in the followup duration, 8 eyes (8/13) had new tumors and (or) recurrences. Finally, 2 eyes (2/13) were enucleated whil e 11 eyes (11/13) were saved in which 8 (8/11) recovered or remained good visual acuity. None of 9 patients had serious side effects of chemotherapy like leucoc ythemia, functional damage of liver and kidney, and dysacousia. Conclus ions：Chem oreduction treatment has well initial effect on advanced RB. Chemoreduction trea tment combined with local treatment may effectively control the retinal tumor, s ubretinal seeds and vitreous seeds within a shortterm duration. The evaluation of longterm effect of the treatment needs further observation.
Objective:To observe the therapeutic effi cacy of chemotherapy combin ed with ophthalmic therapy on retinoblastoma (RB). Methods:The survival rate, eye ball remaining rate, and the control of the disease condition of 37 patients (56 eyes) with RB were retrospectively analyzed. The standard of the well contr ol of the disease included: (1) the ocular tumor shrank or even disappeared, and the tumor had creamlike changes or calcification and cicatrisation; (2) no oc u lar tumor recurrence in patients who had undergone enucleation; (3) no metastasi s found in the followup period. All of the patients had at least one eye with RB (ge;Ⅲb stage) underwent c hemotherapy. According to the response of the tumor to the chemotherapy, the pat ients generally underwent 6 times of systemic chemotherapy at regular intervals of 3-4 weeks. The medicines for chemotherapy included vincristine, cyclohosphamide , etoposide phosphate, and carboplatin. According to the self condition, the pati ents underwent chemotherapy combined with several ophthalmic therapies like phot ocoagulation, cryotherapy, transpupillary thermotherapy, 106Ru brachytherapy, en ucleation, etc. The observation duration lasted 2-59 months, with the average o f 35 months. Results:Thirty patients (83.3%) survived and were followed up, and 6 died (16.6%). One patient with bilateral tumor couldn't be followed up afte renucleation of both eyes. Among these 30 patients (45 eyes), eye ball remainin g rate at stage I-Ⅱ, Ⅲ-Ⅳ, and Ⅴ was 100% (10 eyes), 70% (10 eyes), and 14 .3% (21 eyes), respectively. In the followup duration, the disease in all of the 3 0 patients was controlled well. Conclusions:Chemotherapy combi ned with ophthalmic therapy is effective on RB.
ObjectiveTo evaluate the prognosis of photocoagulation and (or) cryotherapy for prethreshold type 1 and threshold disease of retinopathy of prematurity (ROP).MethodsThe data of 29 eyes of 15 infants who were diagnosed as with prethreshold type 1 or threshold disease of ROP from Jan 30th, 2003 to Jan 13th, 2005 were retrospectively analysed. Pre- and post-operative conditions of ROP were compared in the follow up. Any related local and systemic complications were recorded.ResultsIn 29 eyes which had undergone photocoagulation and (or) cryotherapy, ROP regressed completely in 19 (65.5%), remained dragged retina was found in 7 (24.1%), and retinal detachment was seen in 3 (103%). ROP regressed completely in 12 eyes (41.4%) after the initial treatment and in 7 eyes (24.1%) after the secondary treatment. During the treatment, temporary corneal haze was found in 2 eyes, vitreous hemorrhage occurred in 1 eye, and inadvertent photocoagulation at macular area happened in 1 eye. No systemic complications were found in all cases.ConclusionTimely treatment of photocoagulation and (or) cryotherapy for prethreshold type 1 and threshold disease of ROP may lead to famous prognosis.(Chin J Ocul Fundus Dis,2005,21:278-281)
Objective To investigate the therapeutic effects of retinal angioma. Methods The clinical data of 16 cases(20 e yes) were retrospectively analyzed, and the patients included 5 males and 11 females of 23.3 yeras old on average. Four cases in this series affected by bilateral retinal angiomas were identified as von Hippel-Lindou disease. The retinal an giomas were divided into 5 stages according to their degrees of developmnet from simple angiom without vessel dilation to feeder vessel dilation and intraretina l exudates, local retinal detachemnt, massive retinal detachment and complication occurrence in proper order. The methods of treatment were laser photocoagulati on, trans-scleral cryotherapy and vitreoretinal surgery. The patinets were followed up for 37.8 months on average. Results There were 10 eyes (2 in stage 1, 7 in stage 2, 1 in stage 3)treated with laser photocoagulation, and all of the angiomas were controlled after the treatment. The visual acuity im proved in 2 eyes, decreased in 4 eyes, and remained unchanged in 4 eyes. Cryothe r apy was performed on 7 eyes(5 in stage 3, 2 in stage 4). The visual deteriortion was found in 5 eyes; and the state of illness was stable in 3 eyes in stage 3 a nd aggravating in 4 eyes (2 in stage 3, 2 in stage 4). Vitreoretinal surgery was performed on 4 eyes including 2 which had been given photocoagulation, and the visual acuity improved in 2 eyes, decreased in 1 eye, and was unimproved in 1 ey e . The visual acuity decreased to no light perception in an untreated eye after 1.5 year follow-up. New angiomas occurred in 3 eyes with Von Hippel-Lindou disease in the follow-up period. Conclusion Laser photocoagulation is effective in treating the angiomas from stage 1 to 3. Cryotherapy can cause massive exudation and proliferation, and it is only suitable for a few patients in stage 3. The visual prognosis is more favorable in vitreoretinal surgery tha n other therapies for the patients in stage 4. (Chin J Ocul Fundus Dis, 2001,17:296-298)
Thanks to the treatment of retinoblastoma (RB) having improved significantly in recent years, there is an increasing trend to use conservative treatment modalities that aim to preserve the globe as well as vision with minimum mortality. RB therapy is a long-term systemic treatment in clinical practice. Although there are many treatment options for RB therapy, such as cryotherapy, photocoagulation, systemic chemotherapy, enucleation and ophthalmic chemotherapy, it is recommended to consider in accordance with the following key points in gaining a reasonable treatment strategies: to make sure that RB is an intraocular period; to determine whether the intraocular RB to be treated with eye preservation or enucleation; what is the case of eye preservation therapy combined with chemotherapy and how to arrange the follow-up of RB patients. It's more complicated to choice the therapeutic measures for RB in clinical practice. So, the patient's condition, economic capability and medical condition should be evaluated comprehensively. The principle of RB treatment should be followed, which is protecting eyeball and visual function without life damage.